THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The required details are given in the reply to Starred Question No. 77 for 27th Februray, 1989.

(f) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

Exemption from Price Control of Small Scale Units

617. SHRI CH1TTA BASU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that small scale units are exempted from price control irrespective of sales turnover from Categ-ory-II formulations;

(b) whether it is also a fact that certain small scale units have turnover more than organised sector units;

(c) names of small scale units having annual sales turnover for more than ten crores;

(d) whether it is also a fact that his Ministry has shifted certain drugs from Category I to Category II;

(e) if so, what are the names of those drugs;

(f) whether it is a fact that Kelkar Committee recommended exemption of small scale units with turnover ceiling in the supplementary report;

(g) if so, what are the details thereof; and

(h) what is the position of drugs shifted under price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) and (c) Sales turnover is not monitored by this Ministry.

(d) and (e) Yes, Sir. The following drugs have been shifted from Category-I to Categroy-II of DPCO, 1987;

1. paracetamol.
2. Rifampicin.
3. Timolol.
4. Sulphacetamide Sodium.

(f) and (g) For the ptesent, the Government is not considering withdrawing of the exemption granted to SSI Units vide this Ministry Notificaiton No. S.O. 719(E) dt. 21.7.1988.

(h) The exemption from price control will also be available on such drugs to SSI Units, eligible for exemption from price control under the above said order.

Price Control on Paracetamol Formulations

618. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee recommended price decontrol on paracetamol in its initial report;

(b) on what basis this drug has been price controlled now on the basis of high concentration;

(c) whether **it** is a fact that none of the formulators account for more than 23 per cent of the market of the product;

(d) whether it is a fact that criteria of high concentration has been ignored in the case of Methdilazine, Gly-benelamide, Glipizide, Polymixin B Sulphate, Dulcolax and other medicines where 80 per cent of the market is controlled by one company; and

(e) what are the details of recommen-dations made in the supplementary report in respect of these drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO), (a) to (e) The required details, to the extent available, will be collected and laid on the Table of the House.

DPCO Impact

619. CHOWDHARY RAM SEWAK. Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news item which